EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?

Dan Waitzberg iD, Francisco Guarner iD, Iva Hojsak iD, Gianluca Ianiro iD, D Brent Polk iD, Harry Sokol iD

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-02783-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2024. Verfasst von Dan Waitzberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, LIM-35, School of Medicine, University of São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Lacticaseibacillus rhamnosus, Probiotics, Saccharomyces boulardii. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Biocodex SAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysbiosis corresponds to the disruption of a formerly stable, functionally complete microbiota. In the gut, this imbalance can lead to adverse health outcomes in both the short and long terms, with a potential increase in the lifetime risks of various noncommunicable diseases and disorders such as atopy (like asthma), inflammatory bowel disease, neurological disorders, and even behavioural and psychological disorders. Although antibiotics are highly effective in reducing morbidity and mortality in infectious diseases, antibiotic-associated diarrhoea is a common, non-negligible clinical sign of gut dysbiosis (and the only visible one). Re-establishment of a normal (functional) gut microbiota is promoted by completion of the clinically indicated course of antibiotics, the removal of any other perturbing external factors, the passage of time (i.e. recovery through the microbiota's natural resilience), appropriate nutritional support, and-in selected cases-the addition of probiotics. Systematic reviews and meta-analyses of clinical trials have confirmed the strain-specific efficacy of some probiotics (notably the yeast Saccharomyces boulardii CNCM I-745 and the bacterium Lactobacillus rhamnosus GG) in the treatment and/or prevention of antibiotic-associated diarrhoea in children and in adults. Unusually for a probiotic, S. boulardii is a eukaryote and is not therefore directly affected by antibiotics-making it suitable for administration in cases of antibiotic-associated diarrhoea. A robust body of evidence from clinical trials and meta-analyses shows that the timely administration of an adequately dosed probiotic (upon initiation of antibiotic treatment or within 48 h) can help to prevent or resolve the consequences of antibiotic-associated dysbiosis (such as diarrhoea) and promote the resilience of the gut microbiota and a return to the pre-antibiotic state. A focus on the prescription of evidence-based, adequately dosed probiotics should help to limit unjustified and potentially ineffective self-medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacticaseibacillus rhamnosusProbioticsSaccharomyces boulardiiAdultChildHumansAnti-Bacterial AgentsDiarrheaDysbiosisSaccharomyces cerevisiaeMeta-Analysis as TopicSystematic Reviews as Topic

Stichwörter der Autor:innen

AntibioticsDiarrhoeaDoseDysbiosisProbioticsStrain-specificity

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, LIM-35, School of Medicine, University of São Paulo, São Paulo, Brazil.
  • Teknon Medical Centre, Barcelona, Spain.
  • Referral Centre for Pediatric Gastroenterology and Nutrition, School of Medicine, University of Zagreb, Zagreb, Croatia.
  • University of Zagreb Medical School, Zagreb, Croatia.
  • Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Department of Medical and Surgical Sciences, UOC Gastroenterologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

ORCID-Profile: Dan Waitzberg, Francisco Guarner, Iva Hojsak, Gianluca Ianiro, D Brent Polk, Harry Sokol

Förderung

  • Biocodex SAS

Zitieren

APA

Waitzberg, D., Guarner, F., Hojsak, I., Ianiro, G., Polk, D. B., & Sokol, H. (2024). Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?. Advances in Therapy. https://doi.org/10.1007/s12325-024-02783-3

Vancouver

Waitzberg D, Guarner F, Hojsak I, Ianiro G, Polk DB, Sokol H. Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?. Advances in Therapy. 2024. doi:10.1007/s12325-024-02783-3

BibTeX
@article{Waitzberg2024,
  author = {Waitzberg, Dan and Guarner, Francisco and Hojsak, Iva and Ianiro, Gianluca and Polk, D Brent and Sokol, Harry},
  title = {Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-02783-3}
}
Kostenlos starten →